Dayle Hacking , M.B. Ch. B., M.Med. (Rad) (T)., F.F. Rad. T. (SA)

  • Consultant Radiation Oncologist, UPMC Whitfield Cancer Centre, Waterford, Ireland
  • Medical Director, UPMC Ireland

I am the lead Physician, of three, in the Radiotherapy facility serving the South East of Ireland, providing comprehensive Radiation Oncology services to all patients from the region; a population of approximately 500 000. Our numbers have increased from around a thousand to 1200+ tnew patients per annum, providing Curative and Palliative, 3D and IMRT radiotherapy for all sites. We have implemented IGRT, Respiratory Gating, Deep inspiration breath hold and RapidArc technologies.

Teaching Activities:

· Involved in the teaching of Registrars (Residents) in Oncology and Palliative Medicine who rotate through the local University Hospital in Waterford and in the Academic program of the Faculty of Radiology, Royal College of Radiologists in Ireland (RCSI).

· We have hosted the first observership of Senior Residents in the calendar year 2018 – Drs Zachary Horne and Brian Gebhardt were with us for 6 weeks each between March 12 and June 1.

THREE YEAR BIBLIOGRAPHY

I have two publications from this year, one related to a previous trial conducted with the Irish Co-operative group and one a case report.

(ICORG 05-03): Prospective randomized non-inferiority phase III trial comparing two radiation schedules in malignant spinal cord compression (not proceeding with surgical decompression); the quality of life analysis - K. A. Lee, M. Dunne, C. Small, P. J. Kelly, O. McArdle, J. O’Sullivan, D. Hacking, M. Pomeroy, J. Armstrong, M. Moriarty, A. Clayton-Lea, I. Parker – Acta Oncologica, Volume 57, 2018 - Issue 7, Pages 965-972.

Durable treatment response of relapsing CNS plasmacytoma using intrathecal chemotherapy, radiotherapy, and Daratumumab - Ezzat Elhassadi, Maurice Murphy, Dayle Hacking, and Michael Farrell - Clin Case Rep. 2018 Apr; 6(4): 723–728. Published online 2018 Mar 2. doi: 10.1002/ccr3.1451

Research Interests

Full Member of the Clinical Trials Ireland (CTI) group (formerly ICORG) currently involved in Enzarad (TROG – prostate), TiLarc (CTI – rectal) and FastForward (MRC- Breast hypofractionation) trials.

We have re – thought our research activity and are implementing a Committee on Education and Research with a formal policy associated with this activity. The focus will be three pronged: In house projects focusing on quality related initiative, Formal Trial activity through participation with Co-operative groups (CTI, NRG etc) and a major project related to a recent upgrade of our Aria software (the first unit within the radiotherapy network to use Aria 15.5) and a subsequent optimization project aiming to maximize the use of the care path process to automate the path of patients through the system and generate coherent clinical data to be able to report clinical outcomes (treatment results and toxicity) in real time. Good progress in this area is being made.